The MHRA collects reports of adverse incidents associated with medicines and medical devices via the Yellow Card scheme. Reporting from healthcare professionals has been key for the MHRA assessment of important safety issues such as Breast implant associated-anaplastic large cell lymphoma (BIA-ALCL) and the MHRA is grateful to ABS members for their continued support.
The MHRA have updated the Yellow Card reporting form to capture more specific information about the breast implant and safety specific questions related to Breast implant associated-anaplastic large cell lymphoma (BIA-ALCL). These include prompts for diagnostic markers, presenting symptoms and patient treatment. The aim is to make it easier for surgeons and healthcare professionals to provide this information at the time of reporting and to reduce the burden of additional follow-up questions.
View more information here